# IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer

> **NCT00316745** · PHASE3 · SUSPENDED · sponsor: **Hokkaido Gastrointestinal Cancer Study Group** · enrollment: 200 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Campto, Topotesin
- **DRUG:** TS-1
- **DRUG:** L-Plat
- **DRUG:** Isovorin
- **DRUG:** 5-FU

## Key facts

- **NCT ID:** NCT00316745
- **Lead sponsor:** Hokkaido Gastrointestinal Cancer Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2006-04
- **Primary completion:** —
- **Final completion:** 2009-03
- **Target enrollment:** 200 (ESTIMATED)
- **Why stopped:** Because of approval of Bevacizumab, it was difficult to perform clinical study in 1st line setting.
- **Last updated:** 2007-11-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00316745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00316745, "IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00316745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*